Urologic surgeries concerns the surgical treatment disorders that affect urologic pelvic structures as
cancer of the prostate, adrenal glands, bladder, kidneys, ureters, testicles, and penis1.
Compartment syndrome is a condition in which increased pressure within a limited space which
compromises the circulation and function of the tissues within that space. There are numerous causes of acute
compartment syndrome, including fractures, soft tissue trauma, and prolonged limb compression following drug
overdose, burns, and reperfusion of ischemic tissue, however the most common precipitating factor is traumatic
injury 2.
Well leg compartment syndrome (WLCS)is being increasingly recognized after urological,
gynaecologic, orthopedic or general surgical procedures with the common denominator of patient positioning in
the lithotomy or hemilithotomy position3.The lithotomy position is commonly used to access the pelvis and
perineum during urological, colorectal, and gynecologicalsurgery. Lower limb compartment syndrome is
caused by abnormal increases in intracompartmental pressures within a non-expansile fascial space and has
been recognized after prolonged elevation of the lower limbs during surgical procedures in the lithotomy
position. Commonly compartment syndrome involves ischaemia, hypoxia and oedema4. If prolonged urological
procedure is necessary patient should be monitored post operatively for early and prompt treatment of this
complication. Early diagnosis and proper treatment is the main-stay of the treatment in cases of acute
compartment syndrome following unavoidable prolonged urological procedures in lithotomy position5.
Hyperbaric oxygenation (HBO) therapy is defined as a treatment in which the patient breathes 100%
oxygen at pressures greater than atmospheric; this causes the P02 to increase in proportion to the increase in
ambient pressure. True HBO therapy only refers to the systemic delivery of oxygen via the lungs and is not
related to “topical oxygen therapy, in which only a specific body part is subjected to locally delivered oxygen
under pressure6.
A further form of conservative treatment for compartment syndrome is hyperbaric oxygenation. This
specifically reduces oedema and floods the tissues with oxygen dissolved in the extracellular fluid. This oxygen
is available to the compromised cells without the energy expenditure otherwise required for its transfer from
haemoglobin. In a series of patients with compartment syndrome who were treated with hyperbaric oxygen, that
none progressed and none required a fasciotomy7.

Previous studies indicated that the chloro-benztropine analogs differed significantly in their cocaine-like activity, which was not expected based on the similarity in their in vitro binding affinity and functional potency at the dopamine transporter (DAT). The present study was designed to extend the understanding of the involvement of both pharmacokinetic and pharmacodynamic factors in mediating the behavioral differences among these analogs. The pharmacokinetics of 3'-chloro-3alpha-(diphenylmethoxy)tropane (3'-Cl BZT), the analog showing a cocaine-like behavioral profile in rodents, was compared with previously reported pharmacokinetic characteristics of cocaine and 4',4''-dichloro-3alpha-(diphenylmethoxy)tropane (4',4''-diCl BZT), an analog totally devoid of cocaine-like actions. Microdialysis studies in rats were conducted to determine whether 3'-Cl and 4',4''-diCl BZT differed significantly in their effect on nucleus accumbens extracellular dopamine levels, with cocaine serving as a reference. A mechanistic model based on DAT association/dissociation kinetics was used to describe the time delay between the plasma concentrations of the chloro-analogs and their dopaminergic effects. 3'-Cl BZT had plasma elimination half-life of 1.9 h versus 0.5 and 21.1 h for cocaine and 4',4''-diCl BZT, respectively. 4',4''-diCl BZT increased the DA levels at a slower rate and to a significantly lower extent relative to 3'-Cl BZT that were, in turn, lower than cocaine. The duration of dopamine elevation was as follows: 4',4''-diCl BZT > 3'-Cl BZT > cocaine. The model indicated faster association and dissociation with DAT for 3'-Cl BZT relative to 4',4''-diCl BZT. The present results indicate that behavioral differences among the chloro-analogs may be explainable based on both the dopamine and rate hypotheses of drug abuse.

Among 42 plant species representing the flora of north Sinai, two possessed sand grain sheath encasing the roots. They are Panicum turgidum Forssk. and Stipagrostis scoparia (Trin.and Rupr.) deWinter. Rhizosheaths, compared to surrounding free sand, accommodated higher population density of microorganisms including associative diazotrophs. Isolates secured belonged to the species of Bacillus circulans, Paenib. macerans (Bacillus macerans), Enterobacter agglomerans, Agrobacterium radiobacter and Chryseomonas luteola (Pseudomonos luteola). The rhizosheath potentiality in re-vegetating sand dunes and arid lands, through nitrogen fixation, plant-water relationship and root continuity for nutrient uptake, are discussed. © 2004 Elsevier GmbH. All rights reserved.

ABT-107 is a potent, selective α7 nicotinic receptor agonist under development for treatment of Alzheimer's disease and cognitive deficits associated with schizophrenia. The pharmacokinetics, safety, and tolerability of escalating single oral doses (1, 3, 10, 30, 60, 80, and 100 mg; double-blind, placebo-controlled, randomized, incomplete crossover design) and multiple oral doses (2, 6, and 15 mg once daily for 7 days; double-blind, placebo-controlled, randomized, parallel-group design) of ABT-107 were evaluated. Additionally, effect of food on ABT-107 pharmacokinetics (20-mg single dose) was evaluated using an open-label, 2-period, fasting and nonfasting, randomized, complete crossover design. ABT-107 exhibited nonlinear (more than dose-proportional) pharmacokinetics. ABT-107 half-life ranged from 7 to 10 hours, and steady state was achieved by day 6 of dosing. Food did not have a clinically meaningful effect on ABT-107 exposure. ABT-107 was safe and well tolerated over the tested dose range. The most frequently reported adverse events were nausea, headache, and tremor following single dosing and somnolence following multiple dosing. The pharmacokinetics, safety, and tolerability profiles of ABT-107 pose it as a good candidate for further development.

Aim To characterize quantitatively the relationship between ABT-102, a potent and selective TRPV1 antagonist, exposure and its effects on body temperature in humans using a population pharmacokinetic/pharmacodynamic modelling approach. Methods Serial pharmacokinetic and body temperature (oral or core) measurements from three double-blind, randomized, placebo-controlled studies [single dose (2, 6, 18, 30 and 40 mg, solution formulation), multiple dose (2, 4 and 8 mg twice daily for 7 days, solution formulation) and multiple-dose (1, 2 and 4 mg twice daily for 7 days, solid dispersion formulation)] were analyzed. nonmem was used for model development and the model building steps were guided by pre-specified diagnostic and statistical criteria. The final model was qualified using non-parametric bootstrap and visual predictive check. Results The developed body temperature model included additive components of baseline, circadian rhythm (cosine function of time) and ABT-102 effect (Emax function of plasma concentration) with tolerance development (decrease in ABT-102 Emax over time). Type of body temperature measurement (oral vs. core) was included as a fixed effect on baseline, amplitude of circadian rhythm and residual error. The model estimates (95% bootstrap confidence interval) were: baseline oral body temperature, 36.3 (36.3, 36.4)°C; baseline core body temperature, 37.0 (37.0, 37.1)°C; oral circadian amplitude, 0.25 (0.22, 0.28)°C; core circadian amplitude, 0.31 (0.28, 0.34)°C; circadian phase shift, 7.6 (7.3, 7.9) h; ABT-102 Emax, 2.2 (1.9, 2.7)°C; ABT-102 EC50, 20 (15, 28) ng ml−1; tolerance T50, 28 (20, 43) h. Conclusions At exposures predicted to exert analgesic activity in humans, the effect of ABT-102 on body temperature is estimated to be 0.6 to 0.8°C. This effect attenuates within 2 to 3 days of dosing.

This study is concerned with the electocatalytic evolution of oxygen gas at novel gold nanoparticles (nano-Au) modified glassy carbon (GC) electrodes in 0.5 M KOH. The electrochemical measurements show a superior enhancement of the nano-Au/GC towards the oxygen evolution reaction (OER) compared to bulk GC and Au electrodes. That is, the onset potential of the OER is shifted by ca. 600 mV in the negative direction compared with bulk Au and unmodified GC electrodes. The enrichment in the Au (110) facet orientation (of the electrodeposited nano-Au) [1] at the expense of other low facets orientations induces a favorable geometric arrangements of the Au surface atoms which is believed to facilitate the OH- adsorption and, hence, the charge transfer process during the water electrolysis into molecular oxygen. Thus, the OER is accelerated and realized at less positive potential.

Ambiguity is a major reason why computers do not yet understand natural language. We have made great deal strides towards developing tools for morphological and syntactic analyzers for Arabic in recent years. The absence of diacritics, which represent most vowels, in the written text creates ambiguity which hinders the development of Arabic natural language processing applications. Thus, ambiguity increases the range of possible interpretations of natural language. In this paper, we give a road map of solutions to common ambiguity problems inherent in parsing of Arabic sentence.

AIMS: ABT-288 is a potent and selective H3 receptor antagonist with procognitive effects in several preclinical models. In previous studies, 3 mg once daily was the maximal tolerated dose in healthy volunteers. This study characterized the safety, tolerability and pharmacokinetics of ABT-288 in stable subjects with schizophrenia.

METHODS: This was a randomized, double-blind, placebo-controlled, dose-escalating study of ABT-288 (10 dose levels, from 1 to 60 mg once daily for 14 days) in stable subjects with schizophrenia treated with an atypical antipsychotic. In each dose group, five to seven and two to three participants were assigned to ABT-288 and placebo, respectively.

RESULTS: Of the 67 participants enrolled, nine participants (on ABT-288) were prematurely discontinued, in seven of these due to adverse events. ABT-288 was generally safe and tolerated at doses up to 45 mg once daily. The most common adverse events, in decreasing frequency (from 31 to 5%), were abnormal dreams, headache, insomnia, dizziness, somnolence, dysgeusia, dry mouth, psychotic disorder, parosmia and tachycardia. Adverse events causing early termination were psychotic events (four) and increased creatine phosphokinase, pyrexia and insomnia (one each). The half-life of ABT-288 ranged from 28 to 51 h, and steady state was achieved by day 12 of dosing. At comparable multiple doses, ABT-288 exposure in subjects with schizophrenia was 45% lower than that previously observed in healthy subjects. At trough, ABT-288 cerebrospinal fluid concentrations were 40% of the total plasma concentrations.

CONCLUSIONS: ABT-288 was tolerated at a 15-fold higher dose and 12-fold higher exposures in subjects with schizophrenia than previously observed in healthy volunteers. The greater ABT-288 tolerability was not due to limited brain uptake.